GSK has been the subject of a number of other research reports. Shore Capital reissued a “hold” rating on shares of GlaxoSmithKline in a research report on Tuesday, April 9th. UBS Group set a GBX 1,700 ($22.21) price target on shares of GlaxoSmithKline and gave the company a “buy” rating in a research note on Wednesday, January 2nd. Deutsche Bank set a GBX 1,520 ($19.86) price target on shares of GlaxoSmithKline and gave the company a “neutral” rating in a research note on Tuesday, February 12th. HSBC upped their price target on shares of GlaxoSmithKline from GBX 1,820 ($23.78) to GBX 1,860 ($24.30) and gave the company a “buy” rating in a research note on Thursday, February 7th. Finally, Credit Suisse Group set a GBX 1,600 ($20.91) price target on shares of GlaxoSmithKline and gave the company a “neutral” rating in a research note on Monday, December 17th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating and five have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of GBX 1,526.14 ($19.94).
GSK traded up GBX 4.80 ($0.06) during trading hours on Wednesday, hitting GBX 1,552.20 ($20.28). 6,307,452 shares of the company’s stock were exchanged, compared to its average volume of 9,120,000. GlaxoSmithKline has a 1-year low of GBX 1,408.80 ($18.41) and a 1-year high of GBX 1,648.80 ($21.54). The stock has a market capitalization of $76.70 billion and a price-to-earnings ratio of 21.29. The company has a current ratio of 0.75, a quick ratio of 0.47 and a debt-to-equity ratio of 709.80.
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
See Also: What is the Dividend Aristocrat Index?
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.